Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: A pilot study

Journal of Clinical Psychiatry

Volumn 65, Issue 10, 2004, Pages 1394-1399

  Pallanti, Stefano ^a,b,c   Quercioli, Leonardo ^a   Bruscoli, Matteo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Psichiatria P   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DRUG DERIVATIVE; MIANSERIN; MIRTAZAPINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG COMBINATION; FEMALE; HUMAN; INSOMNIA; MALE; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; ONSET AGE; PILOT STUDY; PREVALENCE; PSYCHOLOGICAL RATING SCALE; PSYCHOSEXUAL DISORDER; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TIME; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; AGE OF ONSET; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CITALOPRAM; COMORBIDITY; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIANSERIN; NAUSEA; OBSESSIVE-COMPULSIVE DISORDER; PILOT PROJECTS; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SINGLE-BLIND METHOD; SLEEP INITIATION AND MAINTENANCE DISORDERS; TIME FACTORS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 16544365329     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n1015     Document Type: Article

References (30)

1. Blier P. Possible neurobiological mechanisms underlying faster onset of antidepressant action. J Clin Psychiatry 2001;62(suppl 4):7-11 (Pubitemid 32183559)
2. Mundo E, Guglielmo E, Bellodi L. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebocontrolled study. Int Clin Psychopharmacol 1998;13:219-224 (Pubitemid 28470313)
3. Saxena S, Brody AL, Ho ML, et al. Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am J Psychiatry 2003;160:522-532 (Pubitemid 41094261)
4. Basson A, Haddjeri N, Blier P, et al. Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur Neuropsychopharmacol 2000;10:177-188 (Pubitemid 30227618)
5. Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRIs? J Clin Psychiatry 2001;62:358-361
6. Szegedi A, Muller MJ, Anghelescu I, et al. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 2003;64:413-420 (Pubitemid 36547285)
7. 2A antagonist. Neuropsychopharmacology 2003;28:402-412
8. Nutt DJ. Tolerability and safety aspects of mirtazapine. Hum Psychopharmacol 2002;17(suppl 1):S37-S41 (Pubitemid 34678890)
9. Pedersen L, Klysner R. Antagonism of SSRI-induced nausea by mirtazapine. Int Clin Psychopharmacol 1997;12:59-60
10. Farah A. Relief of SSRI-induced sexual dysfunction with mirtazapine treatment [letter]. J Clin Psychiatry 1999;60:260-261 (Pubitemid 29193926)
11. Koran LM, Quirk T, Lorberbaum JP, et al. Mirtazapine treatment of OCD. J Clin Psychopharmacol 2001;21:537-538
12. Montgomery SA, Kasper S, Stein DJ, et al. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001;16:75-86 (Pubitemid 32171832)
13. Thomsen PH, Ebbesen C, Persson C. Long-term experience with citalopram in the treatment of adolescent OCD. J Am Acad Child Adolesc Psychiatry 2001;40:895-902 (Pubitemid 32667071)
14. Bezchlibnyk-Butler K, Aleksic I, Kennedy SH. Citalopram: a review of pharmacological and clinical effects. J Psychiatry Neurosci 2000;25: 241-254 (Pubitemid 30641001)
15. Pallanti S, Quercioli L, Paiva RS, et al. Citalopram for resistant obsessivecompulsive disorder. Eur Psychiatry 1999;14:101-106
16. Pallanti S, Koran LM. Citalopram and sexual side effects of selective serotonin reuptake inhibitors [letter]. Am J Psychiatry 1999;156:796 (Pubitemid 29220085)
17. Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry 2002;63:796-801
18. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview forDSM-IV Axis I Disorders, Patient Edition (SCID-I/P, Version 2.0). New York, NY: Biometric Research, New York State Psychiatric Institute; 1995
19. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II). Washington, DC: American Psychiatric Association; 1997
20. National Institute of Mental Health. Clinical Global Impressions (CGI) scale. Psychopharmacol Bull 1985;21:839-843
21. Pauls DL, Hurst CR. Schedule for Tourette and Other Behavioral Disorders (Adult Form, Version A1). New Haven, Conn: Child Study Center, Yale University School of Medicine; 1991
22. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 1: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011
23. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-61
24. DOTES: Dosage Record and Treatment Emergent Symptom Scale. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, rev. ed. Rockville, Md: National Institute of Mental Health; 1976:223-244
25. McGahuey CA, Gelenberg AJ, Lankes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25-40 (Pubitemid 30046590)
26. Carpenter LL, Jocic Z, Hall JM, et al. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 1999;60:45-49 (Pubitemid 29069886)
27. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002;51:183-188 (Pubitemid 34127908)
28. Ruwe FJ, Smulders RA, Kleijn HJ, et al. Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects. Hum Psychopharmacol 2001;16:449-459 (Pubitemid 32895588)
29. Thompson C. Onset of action of antidepressants: results of different analyses. Hum Psychopharmacol 2002;17(suppl 1):S27-S32 (Pubitemid 34678888)
30. Nutt DJ. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr Scand 1997;96(suppl 391):31-37 (Pubitemid 27333216)